Criteria Based Consultation Prescribing Program CRITERIA FOR DRUG COVERAGE Deutetrabenazine (Austedo®)

Notes:

• Quantity limits: Yes

Non-formulary **deutetrabenazine** (**Austedo**[®]) will be covered on the prescription drug benefit when the following criteria are met:

Tardive Dyskinesia:

<u>Initiation (new start) criteria</u>: Non-formulary **deutetrabenazine (Austedo)** will be covered on the prescription drug benefit for 12<u>months</u> when the following criteria are met:

- Prescriber is a neurology or mental health clinician
- Patient has a diagnosis of tardive dyskinesia with symptoms present for at least 3 months
- Patient has history of antipsychotic medication, antidepressant medication, or metoclopramide use
- Abnormal movements are rated as moderate or severe indicated by either:
 - Abnormal Involuntary Movement Scale [AIMS] score ≥10 OR
 - Severity noted to be "moderate" or "severe" by prescriber OR
 - AIMS item 8 score of 3 or 4
- Deutetrabenazine is NOT being used concurrently with another vesicular monoamine transporter 2 (VMAT2) inhibitor, a monoamine oxidase inhibitor (MAOI), or reserpine.

<u>Continued use criteria (12 months after initiation)</u>: Non-formulary <u>deutetrabenazine</u> (<u>Austedo</u>) will continue to be covered on the prescription drug benefit when the following criteria are met:

 Clinically significant improvement in abnormal movements verified by AIMS score or clinician observation

kp.org

Revised: 06/09/22 Effective: 08/04/22 All plans offered and underwritten by Kaiser Foundation Health Plan of the Northwest



Criteria Based Consultation Prescribing Program CRITERIA FOR DRUG COVERAGE Deutetrabenazine (Austedo®)


Chorea associated with Huntington's disease:

<u>Initiation (new start) criteria</u>: Non-formulary deutetrabenazine (Austedo) will be covered on the prescription drug benefit when the following criteria are met:

- Prescriber is a neurology or mental health clinician
- Patient has documented choreiform movements secondary to Huntington's disease that cause impairment to daily activities
- Patient has documented contraindication, intolerance or treatment failure to tetrabenazine
- Deutetrabenazine is NOT being used concurrently with another vesicular monoamine transporter 2 (VMAT2) inhibitor, a monoamine oxidase inhibitor (MAOI), or reserpine

kp.org

Revised: 06/09/22 Effective: 08/04/22



All plans offered and underwritten by

